We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology
News

Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology

Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology
News

Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellzome announced the publication of the article ‘Computational Prediction of Proteotypic Peptides for Quantitative Proteomics’ in this month’s issue of Nature Biotechnology.

In collaboration with the Institute of Systems Biology and the University of California, Los Angeles, Cellzome has mined its proteomic database to systematically investigate the physico-chemical principles governing mass spectrometric peptide sequencing.

Having generated this information, the team then developed software that enabled the genome wide prediction of so-called ‘proteotypic peptides’.

The use of proteotypic peptides can provide an approach to protein identification and to absolute protein quantification. This approach can therefore turn proteomics from a discovery tool into a quantitative biological science.

Tim Edwards, CEO of Cellzome, said: “This publication demonstrates once again the high scientific standard of our core research team. It illustrates one of the many ways in which we are exploiting our massive proteomic database: for the continuous improvement of our technology, for the benefit of our proprietary drug discovery projects, and for the benefit of our collaborations with leading pharmaceutical companies.”

Advertisement